Stratipath co-founders, Mattias Rantalainen and Johan Hartman are receiving the prestigious Karolinska Institutet’s award for innovation and utilisation.
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, and Proscia®, a leading provider of digital and computational pathology solutions, have partnered to help oncologists and pathologists determine the most suitable treatment path for more breast cancer patients.
”AI can be a game-changer” An exclusive interview featuring Stratipath co-founder Johan Hartman in the Swedish wellness magazine ”Må Bra”
More people are living longer with breast cancer – AI can be a game-changer.As October marks Breast Cancer Awareness Month, “Må Bra,” the Swedish wellness magazine, initiates this significant month with an exclusive interview featuring Stratipath co-founder Johan Hartman. The interview delves into topics such as groundbreaking treatments, precision medicine, and the game-changing potential of AI-powered […]
Stratipath has been recognized as one of the innovative healthcare startups hailing from Stockholm.
Excited to share that Stratipath has been recognized as one of the innovative healthcare startups hailing from Stockholm, contributing to the evolution of Sweden’s medical industry. Thanks to EU Startup News for the acknowledgement! ” This startup is working diligently to enhance treatment decisions and outcomes in cancer care. Their work exemplifies the transformative impact of technological […]
Stratipath co-founder Mattias Rantalainen is featured in this article by Healthcareineurope.com
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, and Proscia®, a leading provider of digital and computational pathology solutions, have partnered to help oncologists and pathologists determine the most suitable treatment path for more breast cancer patients.
Professor Jonas Bergh, will be leading our scientific advisory board
Stratipath is happy to announce that one of the most prominent breast oncologists, Professor Jonas Bergh, will be leading the company’s scientific advisory board. As Stratipath is entering the clinical phase with its first-in-class, CE-IVD solution for AI-driven risk profiling, Stratipath breast and at the same time ramping up the research and development efforts for future solutions, the scientific advisory board will play a crucial role in the company’s development.
Stratipath wins innovation prize for advances in AI-based precision oncology
AI-precision oncology pioneers Stratipath have been awarded the Athena Prize, one of Sweden’s most prestigious awards for innovation in health care for the development of their AI-based solution for improved prognostic analysis of breast cancer, using only microscopy images.
Stratipath on prestigious startup-list
Stratipath is listed in tech magazine Ny Teknik’s 33-list, which selects the most promising Swedish start-ups each year.
”The path from academic research to precision diagnostics in routine health care” Stratipath co-founder is writing an article about Stratipath and the research behind in ”Oncology Sweden”. (Swedish only)
Read the article (Swedish only)
The Swedish deep-tech company Stratipath announces its integration with Sectra, one of the most expanding PACS systems for digital pathology
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, today announced that it has released its integration with international medical imaging IT company Sectra and their digital pathology solution. This means that Sectra users can use Stratipath’s solution Stratipath Breast within an already existing digital pathology workflow. The application is featured in Sectra Amplifier Marketplace and purchased directly from Stratipath.
First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients
Stratipath, a global leader in AI-based precision diagnostic solutions, today announced that its AI software for prognostic risk stratification of breast cancers, Stratipath Breast, is now CE-IVD marked. This paves the way for clinical implementation in the European Union. Based on the analysis of digital histopathology whole slide images, stained with haematoxylin and eosin (H&E) the software provides novel decision support to clinicians and enables precision medicine for more patients.